Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11585867 | 0.88 | CA1 (0.39) | TLR4L3MBTL1CA1CA2CA4 | |
| SCHEMBL12225359 | 0.81 | — | — | |
| SCHEMBL1494349 | 0.77 | CRBN (0.42) | L3MBTL1 | |
| SCHEMBL8716246 | 0.72 | PRCP (0.47) | — | |
| SCHEMBL25258771 | 0.71 | — | — | |
| SCHEMBL14085551 | 0.71 | TLR4 (0.31) | TLR4 | |
| SCHEMBL18556394 | 0.70 | L3MBTL1 (0.39) | L3MBTL1 | |
| SCHEMBL22559562 | 0.67 | TLR4 (0.32) | TLR4 | |
| SCHEMBL18997771 | 0.67 | TLR4 (0.33) | TLR4 | |
| SCHEMBL9709156 | 0.66 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141271-A1 | OLIGOMER AND COMPOSITION | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2023-05-11 | — | — | US | disclosed |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| EP-1332132-B1 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | UCB PHARMA SA (BE) | 2007-10-10 | — | — | EP | disclosed |
| US-6780874-B2 | AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIPROLIFERATIVE AGENT | CELLTECH R & D LIMITED (GB) | 2004-08-24 | — | — | US | disclosed |
| US-20030229116-A1 | ENAMINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2003-12-11 | — | — | US | disclosed |
| US-6610700-B2 | Inhibit binding of integrins to their ligands, use in immune or inflammatory disorders; 3-(4-((2,6-Naphthyridinyl)amino)-phenyl)-2-((2-(1-ethylpropyl)-3-oxo-1 -cyclopentenyl) amino)-propionic acid, for example | CELLTECH R & D LIMITED (GB) | 2003-08-26 | — | — | US | disclosed |
| EP-1332132-A2 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | Celltech R&D Limited (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-20020037909-A1 | Enamine derivatives | UCB PHARMA S.A. (BE) | 2002-03-28 | — | — | US | disclosed |
| WO-2001079173-A2 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | CELLTECH R & D LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| US-3959322-A | Synthesis of 13-alkyl-gon-4-ones | Smith, Herchel (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141271-A1 | OLIGOMER AND COMPOSITION | PCNA, ZYX, CCNB2 | TLR4 2173/4885L3MBTL1 1474/4885CA1 2850/4885 |
| US-20020037909-A1 | Enamine derivatives | CCR1, ITGB2, CCR10 | TLR4 422/4885L3MBTL1 1768/4885CA1 4444/4885 |
| US-20030229116-A1 | ENAMINE DERIVATIVES | ITGB2, CCR1, CCR10 | TLR4 340/4885L3MBTL1 1385/4885CA1 4559/4885 |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | NR1H2, NR1H3, NR1H4 | TLR4 778/4885L3MBTL1 2981/4885CA1 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.